Hormonal
Dose-dependent supplementation with prebiotic fibers (inulin and oligofructose) increases satiety hormones (GLP-1, PYY) and alters gut microbiota (increasing Bacteroidetes, decreasing Firmicutes) in lean and obese states, but does not significantly reduce body fat or body weight in a monogenic obesity model.
Eating prebiotic fibers (like inulin) can improve your gut health and boost satiety hormones, which is beneficial for metabolic regulation. However, in some cases, especially with certain genetic predispositions to obesity, this may not automatically result in weight loss. Focus on the health benefits of fiber rather than expecting it to be a standalone weight-loss solution.
Body weight did not differ with prebiotic supplementation in lean or obese rats over the 10-week study... A 25 % reduction in percentage of body fat in lean rats fed the highest dose of fibre did not reach significance... There was a significant effect of the prebiotic on GLP-1... tAUC for GLP-1 was increased in lean 20 % fibre (LHF)... and in obese 20 % fibre (OHF)... Prebiotic fibre dose-dependently increased the Bacteroidetes groups measured... Likewise... prebiotic fibre decreased the Firmicutes groups measured
Why this rating
Controlled animal study with clear dose-response data, but limited to a specific monogenic rat model which may not translate to human polygenic obesity.
Source
Prebiotic fibres dose-dependently increase satiety hormones and alter Bacteroidetes and Firmicutes in lean and obese JCR:LA-cp rats
Jill A. Parnell et al. · British Journal Of Nutrition · 2011
DOI 10.1017/s0007114511003163
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →